Latest News
In this issue:
- President's Corner
- Researcher Spotlight: Laura Cox, PhD
- Study Explains Why Impact of Genetic Risk Factor Varies by Ancestry
- And more!
BrightFocus Foundation’s Alzheimer’s Disease Research program announced a request for scientific proposals for promising research on Alzheimer’s disease and related dementias. The application deadline is November 1, 2022, for projects beginning in 2023.
Major funding from BrightFocus encouraged scientists to pursue an unconventional hypothesis about what may be driving early origins of Alzheimer’s in the brain.
A BrightFocus Alzheimer’s Disease Research grant helped fund an early clinical trial showing that a drug long approved for ALS may have benefits in Alzheimer’s disease.
In this issue:
- President's Corner
- Researcher Spotlight: Timothy Sargeant, PhD
- Researchers Target Recycling System to Prevent Amyloid Plaques
- Alzheimer's: Recreation & Quality of Life
BrightFocus-funded researchers—assisted by a citizen science video game-- were among the first to show that Alzheimer’s contributes to stalls in the brain’s tiniest blood vessels, and they’re working on possible treatments.
Scientists have discovered that a rare version of the so-called “neutral” APOE3 genotype, one they’ve named APOE3-Jacksonville (APOE3-Jac), may help protect against Alzheimer’s through increased lipid binding and cholesterol removal.
Years ago, a BrightFocus grantee said it might be possible to manipulate the blood-brain-barrier to treat Alzheimer’s disease. Now his hypothesis is driving an international effort to develop drugs for this purpose.
Why does the impact of an Alzheimer’s risk factor vary by race and genetic ancestry? Researchers are learning the answers.
BrightFocus Honors the Life of John Q. Trojanowski, MD, PhD
